Literature DB >> 32228178

Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.

Brittany A McKelvey1,2, Timothy Gilpatrick3, Yongchun Wang1, Winston Timp2,3, Christopher B Umbricht1,4,5, Martha A Zeiger6.   

Abstract

Background: Telomerase reverse transcriptase (TERT) promoter mutations play a role in carcinogenesis and are found in both tumors and cancer cell lines. TERT promoter methylation, transcription factor binding, chromatin remodeling, and alternative splicing are also known to play an integral role in TERT regulation.
Methods: Using nanopore Cas9 targeted sequencing, we characterized allele-specific methylation in thyroid cancer cell lines heterozygous for the TERT promoter mutation. Furthermore, using chromatin immunoprecipitation followed by Sanger sequencing, we probed allele-specific binding of the transcription factors GABPA (GA binding protein transcription factor subunit alpha) and MYC, as well as the chromatin marks H3K4me3 and H3K27me3. Finally, using coding single nucleotide polymorphisms and the long-read sequencing, we examined complementary DNA for monoallelic expression (MAE).
Results: We found the mutant TERT promoter allele to be significantly less methylated than wild type, while more methylated in the gene body in heterozygous TERT mutant cell lines. We demonstrated that the transcriptional activators GABPA and MYC bind only to the mutant TERT allele. In addition, the activating and repressive chromatin marks H3K4me3 and H3K27me3, respectively, bind mutant and wild-type alleles exclusively. Finally, in heterozygous mutant cell lines, TERT exhibits MAE from the mutant allele only. Conclusions: In summary, by employing new long-read sequencing methods, we were able to definitively demonstrate allele-specific DNA methylation, histone modifications, transcription factor binding, and the resulting monoallelic transcription in cell lines with heterozygous TERT mutations.

Entities:  

Keywords:  DNA methylation; allele specificity; telomerase; transcriptional regulation

Year:  2020        PMID: 32228178      PMCID: PMC7583328          DOI: 10.1089/thy.2020.0055

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  40 in total

Review 1.  CpG islands and the regulation of transcription.

Authors:  Aimée M Deaton; Adrian Bird
Journal:  Genes Dev       Date:  2011-05-15       Impact factor: 11.361

2.  Minimap2: pairwise alignment for nucleotide sequences.

Authors:  Heng Li
Journal:  Bioinformatics       Date:  2018-09-15       Impact factor: 6.937

3.  Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells.

Authors:  X Yi; J W Shay; W E Wright
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

4.  Direct activation of TERT transcription by c-MYC.

Authors:  K J Wu; C Grandori; M Amacker; N Simon-Vermot; A Polack; J Lingner; R Dalla-Favera
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

5.  Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

Authors:  Xiaoli Liu; Justin Bishop; Yuan Shan; Sara Pai; Dingxie Liu; Avaniyapuram Kannan Murugan; Hui Sun; Adel K El-Naggar; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2013-07-12       Impact factor: 5.678

Review 6.  Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.

Authors:  Satoru Kyo; Masahiro Takakura; Toshiyoshi Fujiwara; Masaki Inoue
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

Review 7.  Nanopore-based fourth-generation DNA sequencing technology.

Authors:  Yanxiao Feng; Yuechuan Zhang; Cuifeng Ying; Deqiang Wang; Chunlei Du
Journal:  Genomics Proteomics Bioinformatics       Date:  2015-03-02       Impact factor: 7.691

8.  Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.

Authors:  Josh Lewis Stern; Dan Theodorescu; Bert Vogelstein; Nickolas Papadopoulos; Thomas R Cech
Journal:  Genes Dev       Date:  2015-10-29       Impact factor: 11.361

9.  Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells.

Authors:  Madeleine P Ball; Jin Billy Li; Yuan Gao; Je-Hyuk Lee; Emily M LeProust; In-Hyun Park; Bin Xie; George Q Daley; George M Church
Journal:  Nat Biotechnol       Date:  2009-03-29       Impact factor: 54.908

10.  Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection.

Authors:  N R Lemoine; E S Mayall; T Jones; D Sheer; S McDermid; P Kendall-Taylor; D Wynford-Thomas
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

View more
  6 in total

Review 1.  Further Introduction of DNA Methylation (DNAm) Arrays in Regular Diagnostics.

Authors:  M M A M Mannens; M P Lombardi; M Alders; P Henneman; J Bliek
Journal:  Front Genet       Date:  2022-07-04       Impact factor: 4.772

Review 2.  TERT-Regulation and Roles in Cancer Formation.

Authors:  Marta Dratwa; Barbara Wysoczańska; Piotr Łacina; Tomasz Kubik; Katarzyna Bogunia-Kubik
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

3.  GABPA protects against gastric cancer deterioration via negatively regulating GPX1.

Authors:  Binghua Yin; Bing Dong; Xiaohui Guo; Can Wang; Huazhi Huo
Journal:  J Med Biochem       Date:  2022-07-29       Impact factor: 2.157

Review 4.  Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.

Authors:  Brittany A McKelvey; Christopher B Umbricht; Martha A Zeiger
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-31       Impact factor: 5.555

Review 5.  Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes.

Authors:  Anna A Plyasova; Dmitry D Zhdanov
Journal:  Biomedicines       Date:  2021-05-09

6.  Multiple ETS Factors Participate in the Transcriptional Control of TERT Mutant Promoter in Thyroid Cancers.

Authors:  Caitlin E M Thornton; Jingzhu Hao; Prasanna P Tamarapu; Iñigo Landa
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.